welbournes

The following price concessions granted in July 2026 have rolled over to August 2026: Drug Pack size Price concession Amiodarone 200mg tablets 28 £5.00 Bendroflumethiazide 2.5mg tablets 28 £0.82 Cyanocobalamin 50microgram tablets 50 £5.95 Enalapril 2.5mg tablets 28 £5.51 Flecainide 50mg tablets 60 £2.21 Haloperidol 5mg tablets 28 £4.55 Itraconazole 100mg capsules 15 £9.30 Rivaroxaban [...]

The post Rolled over price concessions for August 2026 appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has today (04/08/2026) confirmed the following final list of price concessions for July 2026: Drug Pack size Price concession Ascorbic acid 100mg tablets 28 £61.60 Bisoprolol 5mg tablets 28 £0.92 Clonazepam 2mg/5ml oral solution sugar free 150 £49.76 Dapagliflozin 10mg tablets 28 £2.49 Fenofibrate micronised 200mg capsules 28 [...]

The post July 2026 Price Concessions Final Update appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has today (31/07/2026) confirmed the following list of price concessions for July 2026: Please note: Community Pharmacy England has submitted price concession applications for other medicines affected by pricing issues this month. We will issue further updates as soon as we hear back from the Department.  Drug [...]

The post July 2026 Price Concessions 6th Update appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has today (29/07/2026) confirmed the following list of price concessions for July 2026: Please note: Community Pharmacy England has submitted price concession applications for a number of other medicines affected by pricing issues this month. We will issue further updates as soon as we hear back from [...]

The post July 2026 Price Concessions 5th Update appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Tuzulby prolonged-release chewable tablets (Neuraxpharm UK Ltd) Drug alert number: EL(26)A/36 Date issued: 23 July 2026 Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged release 20mg, 30mg and [...]

The post MHRA Class 4 Medicines Defect Notification: Tuzulby prolonged-release chewable tablets (Neuraxpharm UK Ltd) appeared first on Community Pharmacy England.